The Annals Holiday Offer - Save 50%
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


The Annals of Pharmacotherapy: Vol. 34, No. 11, pp. 1273-1275. DOI 10.1345/aph.10028
© 2000 Harvey Whitney Books Company.
This Article
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Horlen, C.
Right arrow Articles by Malouf, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Horlen, C.
Right arrow Articles by Malouf, C.


Research Articles

Toxic metronidazole-induced MRI changes

CK Horlen, CF Seifert, and CS Malouf

OBJECTIVE: To report a case of changes documented by magnetic resonance imaging (MRI) of the head probably due to accumulation of metronidazole in a patient with liver dysfunction. CASE SUMMARY: A 34-year-old Hispanic man with cirrhosis and hepatitis C being treated with metronidazole for Bacteroides fragilis meningitis and bacteremia developed ataxia, disorientation, and peripheral neuropathy. An MRI at the time meningitis was diagnosed was negative. After the patient received > 60 g of metronidazole, an MRI revealed increased signal intensity below, behind, and lateral to the fourth ventricle. Concomitant metronidazole serum concentration was toxic at 35.1 micrograms/mL. DISCUSSION: This is the second reported case of metronidazole-induced MRI changes. Metronidazole is known to accumulate in patients with liver dysfunction and can cause peripheral neuropathy and central nervous system (CNS) dysfunction; these effects may take up to two years to completely resolve. CONCLUSIONS: Metronidazole dosages should be reduced in patients with liver dysfunction to prevent the accumulation of metronidazole, which can lead to CNS dysfunction and peripheral neuropathy.


This article has been cited by other articles:


Home page
Am. J. Neuroradiol.Home page
E. Kim, D.G. Na, E.Y. Kim, J.H. Kim, K.R. Son, and K.H. Chang
MR Imaging of Metronidazole-Induced Encephalopathy: Lesion Distribution and Diffusion-Weighted Imaging Findings
AJNR Am. J. Neuroradiol., October 1, 2007; 28(9): 1652 - 1658.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
J. I. Seok, H. Yi, Y. M. Song, and W. Y. Lee
Metronidazole-Induced Encephalopathy and Inferior Olivary Hypertrophy: Lesion Analysis With Diffusion-Weighted Imaging and Apparent Diffusion Coefficient Maps
Arch Neurol, December 1, 2003; 60(12): 1796 - 1800.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Neuroradiol.Home page
C. J. Heaney, N. G. Campeau, and E. P. Lindell
MR Imaging and Diffusion-Weighted Imaging Changes in Metronidazole (Flagyl)-Induced Cerebellar Toxicity
AJNR Am. J. Neuroradiol., September 1, 2003; 24(8): 1615 - 1617.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
B. K. Woodruff, E. F.M. Wijdicks, and W. F. Marshall
Reversible Metronidazole-Induced Lesions of the Cerebellar Dentate Nuclei
N. Engl. J. Med., January 3, 2002; 346(1): 68 - 69.
[Full Text] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 2000 by Harvey Whitney Books Company.